EHA 2019 | Sotatercept for MPN-associated myelofibrosis and anemia

Srdan Verstovsek

In this video, Srdan Verstovsek, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase II study of sotatercept (ACE-011) (NCT01712308) for myeloproliferative neoplasm (MPN)-associated myelofibrosis or anemia. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video